Anti-Aging Medicine and Reproductive Health

Abstract

Introduction Anti-Aging Medicine belongs to a category of preventive medicine that aims to improve the quality of life (QOL) among older persons 1) . In Japan, morbid aging is assessed by a check up (called an 'Anti-Aging dock') that is based on research into aging mechanisms. We believe that Anti-Aging Medicine can promote health and improve QOL for many elderly persons by allowing them to live independently (care prevention), increasing mobility, and reducing cognition disorder and cancer rates. Given that functional degeneration begins in middle age for both genders, treatments derived from Anti-Aging Medicine may also be applicable in these younger populations, with Anti-Aging coaching and medical treatment helping to improve the health and of these individuals as well as in the elderly. Ovarian function, which has a profound effect on women's health and QOL, may be improved with Anti-Aging Medicine. The holistic application of Anti-Aging Medicine (from an ovary to the whole body and from the whole body to an ovary) may prevent or ameliorate ovarian functional degradation, a response which would subsequently increase fertilization and implantation rates during in vitro fertilization (IVF) and therefore be applicable to general reproductive medicine. Such a holistic approach is based on a therapeutic regimen that may include lifestyle guidance, alimentotherapy, ergotherapy, and counseling, as well as medical therapies, such as functional food, nutritional supplements, anti-oxidation, immune response enhancement, hormone replacement, and aesthetic dermatology. However, the success of such therapies depends on the proper identification of risks associated with aging and individual patient needs. Abstract Given that ovarian function declines with age, older women occasionally experience health or fertility problems. Functional change is influenced by physical, mental, oxidative, and glycation stresses, which may lead to a decline in the secretion of hormones, such as melatonin, growth hormone/insulin-like growth factor-I, and dehydroepiandrosterone (DHEA). Many different factors influence the degradation of ovarian function, and the proper treatment depends on the accurate identification of each patient's condition. Potential degradation mechanisms include the accumulation of advanced glycation end products (AGEs) by glycation stress, and the activation of receptors for AGEs. Accumulated evidence has suggested that in vitro fertilization success rate can be increased on administration of melatonin and DHEA, or glycation stress therapy, to patients with poor ovarian function. The provision of advanced medical technology to rejuvenate ovarian function should be combined with prophylactic lifestyle guidance, such as that developed by Anti-Aging Medicine, to treat the underlying causes of ovarian functional decline. Here, we review the application of Anti-Aging Medicine to aspects of reproductive medicine.